TSH-Receptor Autoantibodies - Differentiation of Hyperthyroidism between Graves' Disease and Toxic Multinodular Goitre

Abstract

Previous studies indicate pre-existing subclinical Graves' disease in many patients with the scintigraphic diagnosis of toxic multinodular goitre type A, equivalent to the in Germany so-called disseminated thyroid autonomy. Furthermore, after radioiodine treatment an increase or the induction of TSH-receptor antibodies (TRAb) in patients with Graves' disease or toxic multinodular goitre has been repeatedly reported.

The distinction between both hyperthyroid conditions, Graves' disease and toxic multinodular goitre type A, depends on the diagnostic power of the TSH-receptor antibody determination. Bioassays using CHO cell lines expressing the hTSH-receptor or a new TBII assay based on competitive binding to recombinant human TSH-receptor showed a higher sensitivity for the detection of TSH-receptor antibodies in patients with Graves' disease than previous assays using solubilized porcine epithelial cell membranes. In up to 50 % of patients with toxic multinodular goitre A without antithyroid drug pretreatment TSH-receptor antibodies were detectable with a high correlation between thyroid-stimulating antibodies in the bioassay and the h-TBII assay. Moreover, in a recent study the development of TSH-receptor antibodies after radioiodine treatment was detectable in 36 % of patients with toxic multinodular goitre type A, whereas TSH-receptor antibodies were not detectable in patients with toxic multinodular goitre type B or in patients with toxic adenoma.

In conclusion, thyroid-stimulating antibodies in a bioassay or TSH-receptor antibodies detected with the h-TBII assay have the highest diagnostic power to differentiate Graves' disease from toxic multinodular goitre. Because of its less cumbersome assay technique the h-TBII should be performed in all patients with hyperthyroidism to differentiate Graves' disease from non-autoimmune hyperthyroidism such as toxic multinodular goitre to select the appropriate therapy for these patients.

Key words

TSH-receptor autoantibodies - Graves' disease - toxic multinodular goitre - hyperthyroidism

References

• 1 Bahre M, Hilgers R, Lindemann C, Emrich D. Thyroid autonomy: sensitive detection in vivo and estimation of its functional relevance using quantified high-resolution scintigraphy.  Acta Endocrinol (Copenh). 1988;  117 145-153
• 2 Carnell N E, Valente W A. Thyroid nodules in Graves' disease: classification, characterization, and response to treatment.  Thyroid. 1998;  8 647-652
• 3 Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.  Clin Endocrinol. 1994;  40 803-806
• 4 Costagliola S, Morgenthaler N G, Hoermann R. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease.  J Clin Endocrinol Metab. 1999;  84 90-97
• 5 DeGroot L J. Radioiodine and the immune system.  Thyroid. 1997;  7 259-264
• 6 Führer D, Warner J, Sequeira M, Paschke R, Gregory J, Ludgate M. Novel TSHR germline mutation (Met463Val) masquerading as Graves' disease in a large Welsh kindred with hyperthyroidism.  Thyroid. 2000;  10 1035-1041
• 7 Gärtner R, Manz F, Grossklaus R. Representative data of iodine intake and urinary excretion in Germany.  Exp Clin Endocrinol Diabetes. 2001;  109 2-7
• 8 Huysmans A K, Hermus R M, Edelbroek M A. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters.  Thyroid. 1997 a;  7 535-539
• 9 Huysmans D, Hermus A, Edelbroek M, Barentsz J, Corstens F, Kloppenborg P. Radioiodine for nontoxic multinodular goiter.  Thyroid. 1997 b;  7 235-239
• 10 Kraiem Z, Glaser B, Yigla M, Pauker J, Sadeh O, Sheinfeld M. Toxic multinodular goiter: a variant of autoimmune hyperthyroidism.  J Clin Endocrinol Metab. 1987;  65 659-664
• 11 Krohn K, Wohlgemuth S, Gerber H, Paschke R. Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations.  J Pathol. 2000;  192 37-42
• 12 Laurberg P, Pedersen K M, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland.  J Intern Med. 1991;  229 415-420
• 13 Massart C, Maugendre D. Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves' disease.  Clin Chem. 2002;  48 102-107
• 14 Morgenthaler N G, Nagata A, Katayama S, Bergmann A, Iitaka M. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor.  Clin Endocrinol (Oxf). 2002;  57 193-198
• 15 Meller J, Jauho A, Hüfner M, Gratz S, Becker W. Disseminated thyroid autonomy or Grabes' disease: reevalution by a second generation TSH receptor antibody assay.  Thyroid. 2000;  10 1073-1079
• 16 Nygaard B, Faber J, Veje A, Hegedus L, Hansen J M. Appearance of Graves'-like 14 disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre.  Clin Endocrinol. 1995;  43 129-130
• 17 Nygaard B, Knudsen J H, Hegedus L, Scient A V, Hansen J E. Thyrotropin receptor 15 antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.  J Clin Endocrinol Metab. 1997;  82 2926-2930
• 18 Nygaard B, Faber J, Veje A, Hegedus L, Hansen J M. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.  Thyroid. 1999 a;  9 477-481
• 19 Nygaard B, Metcalfe R A, Phipps J, Weetman A P, Hegedus L. Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.  J Endocrinol Invest. 1999 b;  22 481-485
• 20 Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.  Nature. 1993;  365 649-651
• 21 Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases.  N Engl J Med. 1997;  337 1675-1681
• 22 Pedersen O M, Aardal N P, Larssen T B, Varhaug J E, Myking O, Vik-Mo H. The value of ultrasonography in predicting autoimmune thyroid disease.  Thyroid. 2000;  10 251-259
• 23 Pedersen I B, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays.  Clin Endocrinol. 2001;  55 381-390
• 24 Rendl J, Juran N, Reiners C. Thyroid volumes and urinary iodine in German school children.  Exp Clin Endocrinol Diabets. 2000;  109 8-12
• 25 Rees S B, McLachlan S M, Furmaniak J. Autoantibodies to the thyrotropin receptor.  Endocr Rev. 1988;  9 106-121
• 26 Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum W A, Seissler J. Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation.  Horm Metab Res. 2000;  32 429-435
• 27 Tonacchera M, Van Sande J, Parma J, Duprez L, Cetani F, Costagliola S, Dumont J E, Vassart G. TSH receptor and disease.  Clin Endocrinol. 1996;  44 621-623
• 28 Vitti P, Elisei R, Tonacchera M. Detection of thyroid stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor.  J Clin Endocrinol Metab. 1993;  76 499-503
• 29 Vitti P. Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease.  Eur J Endocrinol. 2000;  142 22-24
• 30 Wallaschofski H, Kaczmarek M, Miehle K, Hentschel B, Paschke R. Differences between thyrotropin receptor antibody bioactivity and inhibition of 125I-bovine thyrotropin binding.  Thyroid. 2000;  10 897-907
• 31 Wallaschofski H, Orda C, Georgi P, Miehle K, Paschke R. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter.  Horm Metab Res. 2001 a;  33 504-507
• 32 Wallaschofski H, Orda C, Fuhrer D, Holzapfel H P, Krohn K, Miehle K, Neumann S, Georgi P, Paschke R. Distinction between autoimmune and nonautoimmune hyperthyroidism by determination of thyrotropin-receptor antibodies in patients with the scintigraphic diagnosis of disseminated autonomy.  Thyroid. 2001 b;  11 710-711
• 33 Wallaschofski H, Muller D, Georgi P, Paschke R. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment.  Horm Metab Res. 2002;  34 36-39
• 34 Weetman A P. Medical progress: Graves' disease.  N Engl J Med. 2000 a;  343 1236-1248
• 35 Weetman A P. Graves' disease by any other name?.  Thyroid. 2000 b;  10 1071-1072